Congenital heart defects (CHDs) are observed in about 0.8% to 1.0% of live-born new-borns. Owing to advances in prenatal diagnosis, prenatal care, and surgical treatment of CHDs, the prognosis of this population has vastly improved. Despite the satisfactory quality of life after a surgical repair, a considerable percentage of these patients develop symptoms of heart failure in a long-term follow-up. The treatment options in this group are limited. Stem cell research has opened up the possibility to use stem cells in the treatment of end-stage heart failure. It was demonstrated that: 1. In children with CHDs, the mobilization of various types of stem and progenitor cells to peripheral blood is observed. 2. The level of mobilization of stem cell is correlated with individual factors (patient age), factors associated with the pathophysiological features of the defect (hypoxia, pressure overload, volume overload), and factors associated with an acute stress response to a surgery. 3. The mobilization of stem cell is modulated by perioperative factors such as the duration of extracorporeal circulation, the duration of aortic clamping, and the use of medications (nitric oxide, catecholamines). 4. The stimulated regenerative mechanisms may be regulated pharmacologically and their potential may be used in the early postoperative period (modulation of stress response, stimulat ; ion of regeneration and restoration of heart function) as well as in the long-term postoperative period.
pediatria ; kardiochirurgia ; choroby układu krążenia
Mar 10, 2023
Aug 28, 2018
|ZB-127768||Mar 10, 2023|